Compare
Iradimed Corp vs PRO DEX Inc vs Sight Sciences, Inc. vs Kestra Medical Technologies, Ltd.
| Latest fiscal year | Iradimed Corp IRMD | PRO DEX Inc PDEX | Sight Sciences, Inc. SGHT | Kestra Medical Technologies, Ltd. KMTS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-06-30 | 2025-12-31 | 2026-04-30 |
| Revenue | $83.81M | $77.55M | $77.36M | $95.13M |
| Revenue growth (YoY) | +14.4% | +16.5% | -3.1% | +59.0% |
| Gross margin | 76.7% | 31.4% | 86.2% | 51.4% |
| Operating margin | 31.2% | 16.8% | -48.0% | -141.6% |
| Net margin | 26.8% | 17.6% | -49.7% | -138.4% |
| Net income | $22.48M | $13.66M | -$38.43M | -$131.61M |
| EPS (Diluted) | $1.75 | $4.12 | -$0.74 | -$2.43 |
| Operating cash flow | $24.95M | $7.24M | -$29.69M | -$81.70M |
| Free cash flow | $17.18M | $6.76M | -$29.92M | -$116.59M |
| Cash & equivalents | $51.16M | $8.19M | $91.97M | $99.71M |
| Total assets | $108.78M | $74.51M | $115.30M | $358.46M |
| Total liabilities | $14.16M | $26.88M | $51.36M | $98.81M |
| Shareholders' equity | $94.62M | $47.63M | $63.94M | $259.66M |
| Return on year-end equity | 23.8% | 28.7% | -60.1% | -50.7% |
| Shares outstanding | 12.78M | 3.19M | 53.49M | 58.38M |
Revenue, most recent five fiscal years
| Fiscal year | Iradimed Corp | PRO DEX Inc | Sight Sciences, Inc. | Kestra Medical Technologies, Ltd. |
|---|---|---|---|---|
| Latest | $83.81M Ended 2025-12-31 | $77.55M Ended 2026-06-30 | $77.36M Ended 2025-12-31 | $95.13M Ended 2026-04-30 |
| 1 year earlier | $73.24M Ended 2024-12-31 | $66.59M Ended 2025-06-30 | $79.87M Ended 2024-12-31 | $59.81M Ended 2025-04-30 |
| 2 years earlier | $65.56M Ended 2023-12-31 | $53.84M Ended 2024-06-30 | $81.06M Ended 2023-12-31 | $27.81M Ended 2024-04-30 |
| 3 years earlier | $53.30M Ended 2022-12-31 | $46.09M Ended 2023-06-30 | $71.33M Ended 2022-12-31 | n/a |
| 4 years earlier | $41.81M Ended 2021-12-31 | $42.04M Ended 2022-06-30 | $48.96M Ended 2021-12-31 | n/a |